Dopamine receptor agonists for the treatment of early or advanced Parkinsons disease

CNS Drugs

Volumn 24, Issue 11, 2010, Pages 941-968

  Perez Lloret, Santiago ^a,b   Rascol, Olivier ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Apomorphine, therapeutic use; Bromocriptine, therapeutic use; Cabergoline, therapeutic use; Dihydroergocryptine, therapeutic use; Dopamine receptor agonists, adverse reactions; Dopamine receptor agonists, drug interactions; Dopamine receptor agonists, pharmacodynamics; Dopamine receptor agonists, pharmacokinetics; Dopamine receptor agonists, therapeutic use; Drug interactions; Levodopa, therapeutic use; Lisuride, therapeutic use; Parkinsons disease, treatment; Pergolide, therapeutic use; Piribedil, therapeutic use; Pramipexole, therapeutic use; Ropinirole, therapeutic use; Rotigotine, therapeutic use

Indexed keywords

ADROGOLIDE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CIPROFLOXACIN; CLOZAPINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

ANXIETY; BINDING AFFINITY; CLINICAL TRIAL; CONFUSION; DAYTIME SOMNOLENCE; DELUSION; DEPRESSION; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DYSKINESIA; EDEMA; HALLUCINATION; HEADACHE; HEART MUSCLE FIBROSIS; HUMAN; IMPULSE CONTROL DISORDER; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TIMED DRUG RELEASE;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DOPAMINE AGONISTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE;

EID: 77957830241     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11537810-000000000-00000     Document Type: Review

References (231)

1. Birkmayer W, Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinson-ism. Parkinsonism Relat Disord 1998; 4: 59-60
2. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-5
3. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53 Suppl. 3: S3-12
4. Calne DB, Teychenne PF, Leigh PN, et al. Treatment of parkinsonism with bromocriptine. Lancet 1974; 2: 1355-6
5. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Phar-macokinet 2002; 41: 261-309
6. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72: S1-136
7. Kvernmo T, Hartter S, Burger E. A review of the receptorbinding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-78
8. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993; 46: 384-93
9. Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson's disease. Expert Opin Drug Deliv 2005; 2: 1059-73
10. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62: S8-11
11. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999; 37: 257-71
12. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline: rationale for use in Parkinson's disease. Drugs 1998; 55 Suppl. 1: 10-6
13. Albanese A, Colosimo C. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. Acta Neurol Scand 2003; 107: 349-55
14. Biglan KM, Holloway RG. Areview of pramipexole and its clinical utility in Parkinson's disease. Expert Opin Phar-macother 2002; 3: 197-210
15. Blin O. The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol 2003; 16 Suppl. 1: S9-12
16. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 2004; 64: 2125-41
17. Marco AD, Appiah-Kubi LS, Chaudhuri KR. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother 2002; 3: 1481-7
18. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000; 60: 115-37
19. Jenner P, Konen-Bergman M, Schepers C, et al. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009; 31 (11): 2698-711
20. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007; 29: 2654-66
21. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009; 10: 677-91
22. U.S. FDA. FDA approved drug products [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2009 Dec 22]
23. Weber J, Keating GM. Ropinirole prolonged release: in advanced Parkinson's disease. CNS Drugs 2009; 23: 81-90
24. Schapira AH, Albrecht S, Barone P, et al. Inmediate vs delayed-start pramipexole in early Parkinson's disease: the PROUD study [abstract]. Parkinsonism Relat Disord 2009; 15S2: S81
25. Hauser RA, Rascol O, Barone P, et al. Pharmacokinetic profiling of pramipexole extended-release in Parkinson's disease patients: implication for dosing in PD patients with renal insufficiency [abstract]. Mov Disord 2009; 24 Suppl. 1: S265-6
26. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243-54
27. Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37: 2055-60
28. Cawello W, Wolff HM, Meuling WJ, et al. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokinet 2007; 46: 851-7
29. Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dop-amine receptor agonists. Eur J Pharmacol 1996; 312: 35-44
30. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-51
31. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-9
32. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49: S58-62
33. Luquin MR, Laguna J, Obeso JA. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992; 31: 551-4
34. Robertson HA. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 1992; 15: 201-6
35. Gomez-Mancilla B, Bedard PJ. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 1992; 117: 185-8
36. Grondin R, Bedard PJ, Britton DR, et al. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 1997; 49: 421-6
37. Rascol O, Nutt JG, Blin O, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 2001; 58: 249-54
38. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225
39. Maj J, Rogoz Z, Skuza G, et al. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997; 104: 525-33
40. Montastruc JL, Rascol A. Treatment of Parkinson's disease with high doses of bromocriptine: possible interaction with josamycin [in French]. Presse Med 1984; 13: 2267-8
41. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-31
42. Fahn S, Elton RL, members of the UPDRS committee. Unified Parkinson's Disease Rating Scale. In: Mardsen CD, Golstein M, Calne DB, editors. Recent developments in Parkinson's disease. New York: McMillan, 1987: 153-63
43. Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-39
44. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98
45. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, et al. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 1986; 36: 291-3
46. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report: Parkinson's Disease Research Group in the United Kingdom. BMJ 1993; 307: 469-72
47. Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: longterm results of the PRADO study. J Neural Transm 1996; 103: 699-715
48. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-80
49. Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levo-dopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-8
50. Alarcon F, Cevallos N, Lees AJ. Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications? Eur J Neurol 1998; 5: 255-63
51. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; (16): CD006564
52. Herskovits E, Yorio A, Leston J. Long term bromocriptine treatment in de novo Parkinsonian patients. Medicina (B Aires) 1988; 48: 345-50
53. Bakheit AM, Henderson LM, Moore AP, et al. Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease: interim results. Eur Neurol 1990; 30: 108-11
54. Olsson JE, European Multicentric Trial Group. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multi-centric Trial. In: Streifler MB, Korczyn AD, Melamed E, et al. editors. Advances in neurology. Vol. Parkinson's disease: anatomy, pathology, and therapy. New York: Raven Press, 1990
55. Gimenez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997; 20: 67-76
56. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
57. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levo-dopa-controlled study. CNS Drugs 2004; 18: 733-46
58. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23-30
59. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of caber-goline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48: 363-8
60. Bergamasco B, Frattola L, Muratorio A, et al. Alphadihydroergocryptine in the treatment of de novo parkin-sonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand 2000; 101: 372-80
61. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989; 39: 336-9
62. Allain H, Destee A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease: the French Lisuride Study Group. Eur Neurol 2000; 44: 22-30
63. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45: S13-21
64. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-9
65. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006; 21: 343-53
66. Grosset K, Grosset D, Lees A. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Mov Disord 2005; 20: 363-6
67. Rascol O, Dubois B, Caldas AC, et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 2006; 21: 2110-5
68. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuro-pharmacol 1995; 18: 338-47
69. Shannon KM, Bennett Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease: the Pramipexole Study Group. Neurology 1997; 49: 724-8
70. Parkinson's Disease Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-8
71. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713-20
72. Parkinson's Disease Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563-70
73. Poewe WH, Barone P, Hauser RA, et al. Pramipexole extended-release is effective in early Parkinson's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S273
74. Schapira AH, Barone P, Hauser RA, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S277-8
75. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease: the Ropinirole Study Group. Neurology 1997; 49: 393-9
76. Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dop-aminergic therapy in Parkinson's disease. Clin Neuro-pharmacol 1998; 21: 101-7
77. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998; 13: 39-45 (Pubitemid 28029850)
78. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease: the 053 Study Group. Neurology 1999; 53: 364-70
79. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342: 1484-91
80. Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 2002; 9: 253-7
81. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101
82. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006; 21: 1844-50
83. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year followup of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-17
84. Stocchi F, Hersh BP, Scott BL, et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-95
85. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398-404
86. Parkinson's Disease Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-8
87. Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-82
88. Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci 1987; 14: 455-9
89. Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediateto extended-release pramipexole in early Parkinson's disease at the same daily dosage [abstract]. Mov Disord 2009; 24 Suppl. 1: S362
90. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998; 13: 46-51
91. Parkinson's Disease Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43
92. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
93. Dewey Jr RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385-92
94. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996; 47: 785-8
95. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062-5
96. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9: 40-7
97. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9: 431-6
98. Ziegler M, Castro-Caldas A, Del SS, et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease:a 6-month, randomized, placebo-controlled study. Mov Disord 2003; 18: 418-25
99. Castro-Caldas A, Delwaide P, Jost W, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21: 500-9
100. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist prami-pexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicen-tre study. J Neurol Neurosurg Psychiatry 1999; 66: 436-41
101. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bro-mocriptine in advanced Parkinson's disease. Mov Disord 2003; 18: 1149-56
102. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49 (1): 162-8
103. Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease. Coch-rane Database Syst Rev 2000; (3): CD002261
104. Wermuth L, Danish Pramipexole Study Group. A doubleblind, placebo-controlled, randomised, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998; 5: 235-42
105. Murayama S, Narabayashi H, Kowa H, et al. Clinical evaluation of ropinirole hydrochloride in patients with Parkinson's disease: a double-blind comparative study versus bromocriptine mesylate. Japan Pharmacol Ther 1996; 24: 1939-2007
106. Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (3): CD001517
107. Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole iseffective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mov Disord 2007; 22: 1860-5
108. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease: Ropinirole Study Group. Neurology 1998; 51: 1057-62
109. Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (1): CD001516
110. Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002; 109: 489-502
111. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease: International Pramipexole-Bromo-criptine Study Group. Neurology 1997; 49: 1060-5
112. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-10
113. Martignoni E, Pacchetti C, Sibilla L, et al. Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial. Clin Neuropharmacol 1991; 14: 78-83
114. Navan P, Findley LJ, Undy MB, et al. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12: 1-8
115. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-7
116. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-20
117. Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand 1992; 86: 593-5
118. LeWitt PA, GopinathanG, Ward CD, et al. Lisuride versus bromocriptine treatment in Parkinson disease: a doubleblind study. Neurology 1982; 32: 69-72
119. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-14
120. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999; 14: 38-44
121. Koller W, Lees A, Doder M, et al. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001; 16: 858-66
122. Kumar N, Van Gerpen JA, Bower JH, et al. Levodopadyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20: 342-4
123. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromo-criptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-10
124. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-9
125. Stocchi F, Kakarieka A, Kieburtz K, et al. The STRIDE-PD study: late breaking abstracts. 13th International Congress of Parkinson's Disease and Movement Disorders [online]. Available from URL: http://www.movementdi sorders.org/congress/congress09/late-breaking-abstracts.pdf [Accessed 2009 Dec 1]
126. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 75-81
127. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2): CD000236
128. Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (2): CD000235
129. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-45
130. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-15
131. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 58: 681-7
132. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using singledose challenges. Mov Disord 2005; 20: 151-7
133. Garcia Ruiz PJ, Sesar IA, Ares PB, et al. Efficacy of longterm continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23: 1130-6
134. Yanagisawa N, Kowa H, Mizuno Y, et al. The clinical evaluation of CG-101 (cabergoline) in Parkinson's disease patients with L-DOPA: a multi-centred phase III doubleblind comparative study vs. bromocriptine mesilate. J Clin Ther Med 1996; 12 (17): 12
135. Clarke CE, Deane KH. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (1): CD001519
136. Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243: 68-72
137. Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; (1): CD001518
138. Deuschl G, Vaitkus A, Fox GC, et al. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 2007; 22: 1550-5
139. Im JH, Ha JH, Cho IS, et al. The efficacy and safety of ropinirole as an adjunct to levodopa in Korean patients with Parkinson's disease. Parkinsonism Relat Disord 1999; 5: S75
140. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985; 35: 199-206
141. Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism: a nation-wide collaborative double-blind study. Acta Neurol Scand 1985; 72: 157-70
142. Stocchi F. Use of apomorphine in Parkinson's disease. Neurol Sci 2008; 29 Suppl. 5: S383-6
143. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-6
144. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235-41
145. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dys-kinesias. Mov Disord 1996; 11: 327-9
146. Cristina S, Zangaglia R, Mancini F, et al. High-dose ropinirole in advanced Parkinson's disease with severe dys-kinesias. Clin Neuropharmacol 2003; 26: 146-50
147. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-74
148. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65
149. Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60
150. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61: 127-32
151. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307-14
152. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001; 34: 137-41
153. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406
154. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601-7
155. Barone P, Poewe W, Tolosa E, et al. Efficacy of doubleblind, placebo-controlled pramipexole against depression in Parkinson's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S347
156. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008; 22: 563-86
157. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53
158. Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 2006; 9: 28-38
159. Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31: 261-6
160. Happe S, Berger K. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease: a prospective study. J Neurol 2001; 248: 1062-7
161. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009; 72: S44-50
162. Gerlach M, Double KL, Youdim MB, et al. Strategies for the protection of dopaminergic neurons against neuro-toxicity. Neurotox Res 2000; 2: 99-114
163. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905-12
164. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207-13
165. Clow A, Freestone C, Lewis E, et al. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993; 164: 41-3
166. Kakimura J, Kitamura Y, Takata K, et al. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 2001; 417: 59-67
167. Gu M, Iravani MM, Cooper JM, et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004; 91: 1075-81
168. Chau KY, Korlipara LV, Cooper JM, et al. Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J Neurol Sci 2009; 278: 44-53
169. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208-15
170. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9
171. Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006; 73: 629-32
172. Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res 2008; 18 Suppl. 1: 14-8
173. Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22: 1543-9
174. Biglan KM, Holloway Jr RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69: 187-95
175. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115-38
176. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041-2
177. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-63
178. Diederich NJ, Fenelon G, Stebbins G, et al. Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 5: 331-42
179. Fujimoto K. Management of non-motor complications in Parkinson's disease. J Neurol 2009; 256 Suppl. 3: 299-305
180. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32: 475-88
181. Rossi M, Gerschcovich ER, de Achaval D, et al. Decisionmaking in Parkinson's disease patients with and without pathological gambling. Eur J Neurol 2010; 17: 97-102
182. Voon V, Fox SH. Medication-related impulse control and repetitive
183. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking prami-pexole and ropinirole. Neurology 1999; 52: 1908-10
184. Homann CN, Suppan K, Wenzel K, et al. Sleep attacks with apomorphine. Wien Klin Wochenschr 2002; 114: 430-1
185. Ferreira JJ, Galitzky M, Montastruc JL, et al. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355: 1333-4
186. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355: 1332-3
187. Tan EK. Piribedil-induced sleep attacks in Parkinson's disease. Fundam Clin Pharmacol 2003; 17: 117-9
188. Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonistinduced sleep attacks. Pharmacotherapy 2000; 20: 724-6
189. Santens P. Sleep attacks in Parkinson's disease induced by entacapone, a COMT-inhibitor. Fundam Clin Pharmacol 2003; 17: 121-3
190. Ferreira JJ, Thalamas C, Montastruc JL, et al. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. J Neurol 2001; 248: 426-7
191. Ferreira JJ, Desboeuf K, Galitzky M, et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006; 13: 209-14
192. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-63
193. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-67
194. Etminan M, Samii A, Takkouche B, et al. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863-8
195. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922-7
196. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102
197. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001; 24: 181-3
198. Manni R, Terzaghi M, Sartori I, et al. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med 2004; 5: 189-93
199. Schlesinger I, Ravin PD. Dopamine agonists induce episodes of irresistible daytime sleepiness. Eur Neurol 2003; 49: 30-3
200. Korner Y, Meindorfner C, Moller JC, et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 2004; 19: 1298-305
201. Brodsky MA, Godbold J, Roth T, et al. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-72
202. Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology 2002; 58: 460-2
203. Micallef J, Rey M, Eusebio A, et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009; 67: 333-40
204. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324: 1483-7
205. Hauser RA, Wahba MN, Zesiewicz TA, et al. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000; 15: 1269-71
206. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636-9
207. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287-93
208. Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf 2000; 23: 143-64
209. Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991; 30: 613-6
210. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999; 74: 371-5
211. Mondal BK, Suri S. Pergolide-induced retroperitoneal fibrosis [letter]. Int J Clin Pract 2000; 54: 403
212. Shaunak S, Wilkins A, Pilling JB, et al. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999; 66: 79-81
213. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004; 19: 699-704
214. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-62
215. Vergeret J, Barat M, Taytard A, et al. Pleuropulmonary fibrosis and bromocriptine. Sem Hop 1984; 60: 741-4
216. Steiger M, Jost W, Grandas F, et al. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 2009; 116: 179-91
217. Rascol O, Pathak A, Bagheri H, et al. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004; 19: 1524-5
218. Rascol O, Pathak A, Bagheri H, et al. New concerns about old drugs: valvular heart disease on ergot derivative dop-amine agonists as an exemplary situation of pharma-covigilance. Mov Disord 2004; 19: 611-3
219. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004; 62: S32-6
220. Poewe W, Kleedorfer B, Wagner M, et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow-up in 18 patients. Adv Neurol 1993; 60: 656-9
221. Warshaw EM, Paller AS, Fowler JF, et al. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther 2008; 30: 326-37
222. Fabre N, Montastruc JL, Rascol O. Alopecia: an adverse effect of bromocriptine. Clin Neuropharmacol 1993; 16: 266-8
223. Burchill SA, Thody AJ, Ito S. Melanocyte-stimulating hormone, tyrosinase activity and the regulation of eu-melanogenesis and phaeomelanogenesis in the hair follic-ular melanocytes of the mouse. J Endocrinol 1986; 109: 15-21
224. Thody AJ, Ridley K, Carter RJ, et al. Alpha-MSH and coat color changes in the mouse. Peptides 1984; 5: 1031-6
225. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res 2009; 88: 386-97
226. Pinter MM, Helscher RJ, Mundsperger N, et al. Transient increase of pancreatic enzymes evoked by apomorphine in Parkinson's disease. J Neural Transm 1998; 105 (10-12): 1237-44
227. Lane RJ, Routledge PA. Drug-induced neurological disorders. Drugs 1983; 26: 124-47
228. Muller T, Przuntek H, Kuhlmann A. Loss of color vision during long-term treatment with pramipexole. J Neurol 2003; 250: 101-2
229. Sweetman SC. Martindale: the complete drug reference [online]. Available from URL: http://www.medicines complete.com/mc/martindale/current/[Accessed 2009 Jun 1]
230. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929-37
231. Moller JC, Eggert KM, Unger M, et al. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol 2008; 15 Suppl. 2: 15-23